bbt-401-1s
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2018 (NCT03482648)
Timeline
Indications
Studied for
Mechanism of action
inhibitor - Pellino-1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04596293 | Phase 2 | Jan 31, 2021 | Bridge Biotherapeutics, Inc., Covance |
| NCT04478825 | Phase 1 | Oct 30, 2020 | Bridge Biotherapeutics, Inc., Covance |
| NCT03482648 | Phase 1 | Mar 20, 2018 | Bridge Biotherapeutics, Inc., KCRN Research |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bridge Biotherapeutics, Inc. | For profit | 3 | 3 | 2 | 2018 |
| Covance | For profit | 2 | 0 | 2 | 2020 |
| KCRN Research | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1